Advertisement
UK markets open in 6 hours 1 minute
  • NIKKEI 225

    37,621.52
    -6.96 (-0.02%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • CRUDE OIL

    83.85
    +0.28 (+0.34%)
     
  • GOLD FUTURES

    2,341.70
    -0.80 (-0.03%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,411.79
    -221.75 (-0.43%)
     
  • CMC Crypto 200

    1,387.16
    +4.59 (+0.33%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

Does Accelerate Diagnostics’ Financial Performance Bode Well?

Does Accelerate Diagnostics’ Financial Performance Bode Well?

How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.